President & CEO at Adaptive Biotechnologies Corporation
Location:
Seattle, Washington
Industry:
Biotechnology
Work:
Adaptive Biotechnologies Corporation since Sep 2009
President & CEO
Connaught Real Estate Finance Sep 2007 - Jan 2009
President & COO
Pulte Homes Jul 2003 - Sep 2006
VP Operations
Healthaxis 1999 - 2000
Director of Business Development
Wasserstein Perella 1997 - 1999
Associate
Education:
University of Pennsylvania - The Wharton School 2000 - 2002
Master of Business Administration (MBA), Finance and Marketing
Cornell University 1992 - 1996
Bachelor of Science (BS), Entrepreneurship/Entrepreneurial Studies
Honor & Awards:
MBA, Seattle 40 Under 40
Senior Chemist At Chevron Phillips Chemical Company
Senior Chemist at Chevron Phillips Chemical Company
Location:
Amarillo, Texas Area
Industry:
Chemicals
Work:
Chevron Phillips Chemical Company since Aug 2007
Senior Chemist
Education:
University of Cincinnati 2001 - 2005
Doctor of Philosophy (PhD), Analytical Chemistry
Southern University and Agricultural and Mechanical College at Baton Rouge 1995 - 1999
Bachelor of Applied Science (B.A.Sc.), Chemistry
Aug 2007 to 2000 Senior ChemistORAU Cincinnati, OH May 2005 to Aug 2007 Post Doctoral Research AssociateUniversity of Cincinnati Cincinnati, OH May 2001 to May 2005 Graduate Research AssistantLouisiana State University Baton Rouge, LA Aug 1999 to May 2001 Graduate Research Assistant
Education:
University of Cincinnati Cincinnati, OH 1999 to 2005 Ph. D. in ChemistrySouthern University Baton Rouge, LA 1995 to 1999 B.S. in Chemistry
Speaking at an investor conference last week, prior to the authorization, the companys CEO, Chad Robins, called the test the first stepping stone in what Ill call a franchise of T-Detect products.
Date: Mar 08, 2021
Category: More news
Source: Google
How to make millions from the race for a coronavirus vaccine
But just four of the CEOs of those firms, including Bancel, have sold company stock. Only one - Chad Robins of Adaptive Biotech - made substantial, regular sales under a 10b5-1 plan, like Moderna's Bancel. Adaptive Biotech, however, has seen a far smaller recent stock-price increase - about 50 perc